Kennedy, to the Commissioner of Texas Agriculture, Sid Miller, everyone is talking about water, and what’s going inside it.
In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
Today’s 6 in the City segment features host Stephanie McCoy and guest Dr. Jordan Heimer, DMD, the Head of Restorative for ...
Newborn screening is transforming, as advances in genomic sequencing pave the way for earlier, more accurate diagnoses of ...
Mitchell: Officially, by the first birthday, or within six months of the first tooth’s coming in. The first appointment is ...
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...